Physostigmine: Difference between revisions
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Anticholinergic toxicity]]=== | ===[[Anticholinergic toxicity]]=== | ||
*0.5- | *0.5-2 mg IV over 5 min | ||
===Non-depolarizing neuromuscular blockade reversal=== | |||
*0.5-1 mg IM/IV q10 min prn | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Revision as of 19:53, 7 October 2018
General
- Type: acetylcholinesterase inhibitor
- Dosage Forms: IV/IM
- Common Trade Names: Antilirium
Adult Dosing
Anticholinergic toxicity
- 0.5-2 mg IV over 5 min
Non-depolarizing neuromuscular blockade reversal
- 0.5-1 mg IM/IV q10 min prn
Pediatric Dosing
- .02mg/kg repeat every 5-10 minutes until adequate response, max of 2mg
- no faster than .5mg/min
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
- Side effects: bradycardia, dysrhythmias, cholinergic excess
- Always have atropine at the bedside for bradycardia or cholinergic excess
Pharmacology
- Reversible AChE inhibitor, that increases concentration of acetylcholine
- Indirectly stimulates both nicotinic and muscarinic ACh receptors
- Metabolism via CYP450
- Excretion minimally via urine
- Onset of action: 15-20min